PROMETHEUS BIOSCIENCES

prometheus-biosciences-logo

Prometheus Biosciences, Inc., former Prometheus Laboratories, Inc., a specialty pharmaceutical company, engages in developing and commercializing novel pharmaceutical and diagnostic products to help physicians individualize patient care. It markets and promotes Entocort EC, a glucocorticosteroid, which is indicated for the induction and maintenance of clinical remission in mild to moderately active Crohn's disease involving the ileum and/or the ascending colon. It has an agreement to acquire rig... hts to LOTRONEX tablets, which is used in female patients with diarrhea-predominant irritable bowel syndrome; and an agreement to develop and commercialize COLAL-PRED, a development-stage product for the treatment of gastrointestinal diseases or other applications. The company also sells other branded drugs, including Imuran for use as an adjunct for the prevention of rejection in kidney transplantation and the management of active rheumatoid arthritis, Helidac Therapy for use together with an H2 antagonist for the eradication of helicobacter pylori bacteria, and Ridaura for the management of rheumatoid arthritis. In addition, Prometheus Laboratories sells a generic formulation of mercaptopurine, which is approved as maintenance therapy for acute lymphatic leukemia as part of a combination regimen through third-party distributors. Further, it provides diagnostic testing services, including specific immunoassays to detect and differentiate diseases, pharmacogenetic testing, and drug metabolite monitoring; and tests that assist physicians in using and monitoring thiopurine drugs and the detection, diagnosis, or treatment of celiac disease, lactose intolerance, and other related disorders. Prometheus Laboratories, Inc. was founded in 1995 and is headquartered in San Diego, California.

#SimilarOrganizations #People #Financial #Event #Website #More

PROMETHEUS BIOSCIENCES

Social Links:

Industry:
Biotechnology Health Diagnostics Pharmaceutical Therapeutics

Founded:
1995-01-01

Address:
San Diego, California, United States

Country:
United States

Website Url:
http://www.prometheusbiosciences.com

Total Employee:
501+

Status:
Active

Contact:
858-824-0895

Email Addresses:
[email protected]

Total Funding:
951.84 M USD

Technology used in webpage:
Domain Not Resolving Mobile Non Scaleable Content Cloudflare Hosting Nginx Person Schema Amazon Virginia Region Apache 2.4 Amazon Route 53 Java EE OpenSSL


Similar Organizations

aclaris-therapeutics-logo

Aclaris Therapeutics

Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.

adamas-pharmaceuticals-logo

Adamas Pharmaceuticals

Adamas Pharmaceuticals develops controlled release combination therapeutics for infectious diseases and central nervous system disorders.

advaxis-logo

Advaxis

Advaxis is a developer of multiple cancer immunotherapies based on its proprietary platform that redirects the immune system to kill cancer.

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

cypress-bioscience-logo

Cypress Bioscience

Cypress Bioscience provides therapeutics and personalized medicine services to facilitate improved and individualized patient care.

pliant-therapeutics-logo

Pliant Therapeutics

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

radius-health-logo

Radius Health

Radius Health develops drug therapies for osteoporosis and women’s health.


Current Advisors List

adam-stone_image

Adam Stone Board of Directors @ Prometheus Biosciences
Board_member
2020-11-09

luis-cantarell_image

Luis Cantarell Chairman of the Board of Directors @ Prometheus Biosciences
Board_member

adam-stone_image

Adam Stone Board Member @ Prometheus Biosciences
Board_member
2020-11-01

not_available_image

Joy Ghosh Board of Directors @ Prometheus Biosciences
Board_member
2020-11-09

joseph-c-papa_image

Joseph C. Papa Member Board of Directors @ Prometheus Biosciences
Board_member
2020-08-01

Current Employees Featured

allison-luo_image

Allison Luo
Allison Luo Chief Medical Officer @ Prometheus Biosciences
Chief Medical Officer
2018-08-01

olivier-laurent_image

Olivier Laurent
Olivier Laurent Chief Scientific Officer and Head of R&D @ Prometheus Biosciences
Chief Scientific Officer and Head of R&D
2020-09-01

keith-w-marshall_image

Keith W. Marshall
Keith W. Marshall Chief Financial Officer @ Prometheus Biosciences
Chief Financial Officer
2020-08-01

thierry-dervieux_image

Thierry Dervieux
Thierry Dervieux Chief Development Officer Diagnostics @ Prometheus Biosciences
Chief Development Officer Diagnostics
2019-12-01

lauren-g-otsuki_image

Lauren G. Otsuki
Lauren G. Otsuki Chief Operating Officer @ Prometheus Biosciences
Chief Operating Officer

mira-huyghe_image

MiRa Huyghe
MiRa Huyghe VP, Clinical Operations @ Prometheus Biosciences
VP, Clinical Operations
2020-01-01

evan-mcclure_image

Evan McClure
Evan McClure Chief of Staff & Vice President, Business Operations @ Prometheus Biosciences
Chief of Staff & Vice President, Business Operations
2021-01-01

nori-ebersole_image

Nori Ebersole
Nori Ebersole Chief People Officer @ Prometheus Biosciences
Chief People Officer
2021-04-01

erik-reinertsen_image

Erik Reinertsen
Erik Reinertsen Director, Data Science and Engineering @ Prometheus Biosciences
Director, Data Science and Engineering
2021-02-01

Founder


mark-mckenna_image

Mark McKenna

scott-glenn_image

Scott Glenn

Stock Details


Company's stock symbol is NASDAQ:RXDX

Investors List

cowen-healthcare-investments_image

Cowen Healthcare Investments

Cowen Healthcare Investments investment in Private Equity Round - Prometheus Biosciences

cedars-sinai-medical-centerr_image

Cedars Sinai

Cedars Sinai investment in Private Equity Round - Prometheus Biosciences

nestl_image

Nestlé

Nestlé investment in Private Equity Round - Prometheus Biosciences

agi-partners_image

AGI Partners

AGI Partners investment in Private Equity Round - Prometheus Biosciences

cormorant-capital_image

Cormorant Capital

Cormorant Capital investment in Private Equity Round - Prometheus Biosciences

rtw-investments-llc_image

RTW Investments

RTW Investments investment in Private Equity Round - Prometheus Biosciences

eventide-asset-management_image

Eventide

Eventide investment in Private Equity Round - Prometheus Biosciences

point72_image

Point72

Point72 investment in Private Equity Round - Prometheus Biosciences

irving-investors_image

Irving Investors

Irving Investors investment in Private Equity Round - Prometheus Biosciences

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Private Equity Round - Prometheus Biosciences

Key Employee Changes

Date New article
2020-08-04 Prometheus Taps Conatus’s Marshall as Its Chief Financial Officer

Official Site Inspections

http://www.prometheusbiosciences.com Semrush global rank: 3.12 M Semrush visits lastest month: 4.9 K

  • Host name: lax17s38-in-f14.1e100.net
  • IP address: 172.217.14.78
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Prometheus Biosciences"

Prometheus Biosciences - Crunchbase Company Profile & Funding

Contact Email [email protected] Phone Number 858-824-0895 Prometheus Biosciences, Inc., former Prometheus Laboratories, Inc., a specialty pharmaceutical company, …See details»

Merck Completes Acquisition of Prometheus Biosciences, Inc.

Jun 16, 2023 RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus …See details»

What can we help you find? - Merck

Apr 16, 2023 Copies of the documents filed with the SEC by Prometheus may be obtained at no charge on Prometheus’ internet website at https://www.prometheusbiosciences.com or by …See details»

MSD Completes Acquisition of Prometheus Biosciences, Inc.

Jun 16, 2023 Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions …See details»

Prometheus Biosciences, Inc. | LinkedIn

Prometheus Biosciences, Inc. Biotechnology Research San Diego, California 8,044 followers Revolutionizing medicine with precision.See details»

Acquisition of Prometheus Biosciences

Apr 17, 2023 charge on Prometheus Biosciences’ internet website at www.prometheusbiosciences.com or by contacting Prometheus Biosciences at 3050 Science …See details»

Prometheus Biosciences - PitchBook

Prometheus Biosciences General Information Description. Prometheus Biosciences Inc is a biotechnology company pioneering a precision medicine approach to the discovery, …See details»

Prometheus Biosciences - Craft

Jun 16, 2023 Prometheus Biosciences has 3 employees at their 1 location and $6.81 m in annual revenue in FY 2022. See insights on Prometheus Biosciences including office …See details»

Board of Directors | Prometheus Biosciences

Helen C. Adams, CPA, has been a member of our Board of Directors since February 2021. From January 2013 to March 2018, Ms. Adams was the San Diego Area Managing Partner for …See details»

Prometheus Biosciences, Inc. Announces Proposed Public Offering …

SAN DIEGO, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for …See details»

Prometheus Biosciences Announces $130 Million Financing to …

Nov 9, 2020 For more information about Prometheus, please visit www.prometheusbiosciences.com. Contacts: Investor Relations and Media Contact Juniper …See details»

Merck | Home

At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improve lives.See details»

Prometheus Biosciences Achieves Milestone Payment from Dr.

-Prometheus receives $10 million payment triggered by selection of clinical candidate for PR600- -IND for PR600 expected in 3Q 2022- SAN DIEGO, June 21, 2021 (GLOBE NEWSWIRE) -- …See details»

Merck Strengthens Immunology Pipeline with Acquisition of

Apr 16, 2023 Copies of the documents filed with the SEC by Prometheus may be obtained at no charge on Prometheus’ internet website at https://www.prometheusbiosciences.com or by …See details»

Prometheus Biosciences Reports Fourth Quarter and Full-Year …

Feb 28, 2023 Prometheus’ Phase 2 ARTEMIS-UC clinical trial was a 12-week, double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of PRA023 in …See details»

Prometheus Biosciences Announces Upsized Pricing of Initial …

SAN DIEGO, March 11, 2021 /PRNewswire/ -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a biotechnology company pioneering a precision medicine approach for the discovery, …See details»

Merck Strengthens Immunology Pipeline with Acquisition of …

Apr 16, 2023 Copies of the documents filed with the SEC by Prometheus may be obtained at no charge on Prometheus’ internet website at https://www.prometheusbiosciences.com or by …See details»

Prometheus Biosciences Reports Fourth Quarter and Full-Year

Feb 28, 2023 [email protected]. Media contact: Juniper Point Amy Conrad (858) 914-1962 [email protected]. Tags RXDX 4Q 2023 Earnings ...See details»

Prometheus Biosciences Reports First Quarter 2022 Financial …

May 12, 2022 - Advanced and expanded development of PRA023 across three immune-mediated indications - - Topline results from ARTEMIS-UC and APOLLO-CD Phase 2 studies …See details»

Prometheus Biosciences Announces Positive Results for PRA023 in …

Dec 7, 2022 – ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – …See details»

linkstock.net © 2022. All rights reserved